

Bo Abrahamsen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3702981/bo-abrahamsen-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

245
papers

10,936
citations

52
h-index

96
g-index

276
ext. papers

12,730
ext. citations

5.2
avg, IF

6.56
L-index

#	Paper	IF	Citations
245	Newly Diagnosed Celiac Disease and Bone Health in Young Adults: A Systematic Literature Review.. <i>Calcified Tissue International</i> , 2022 , 1	3.9	1
244	Regulation of bone mass in endocrine diseases including diabetes.. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2022 , 101614	6.5	0
243	Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database.. <i>Osteoporosis International</i> , 2022 , 1	5.3	0
242	Utility of PINP to monitor osteoporosis treatment in primary care, the POSE study (PINP and Osteoporosis in Sheffield Evaluation).. <i>Bone</i> , 2022 , 158, 116347	4.7	0
241	The effect of parathyroidectomy compared to non-surgical surveillance on kidney function in primary hyperparathyroidism: a nationwide historic cohort study.. <i>BMC Endocrine Disorders</i> , 2022 , 22, 14	3.3	1
240	Osteoarthritis in osteogenesis imperfecta: A nationwide register-based cohort study. <i>Bone</i> , 2022 , 154, 116222	4.7	0
239	Fractures following pregnancy in Osteogenesis imperfecta - A self-controlled case series using Danish Health Registers. <i>Bone</i> , 2022 , 154, 116177	4.7	
238	FREM predicts 10-year incident fracture risk independent of FRAX [®] probability: a registry-based cohort study.. <i>Osteoporosis International</i> , 2022 , 1	5.3	0
237	Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study. <i>Health Technology Assessment</i> , 2021 , 25, 1-106	4.4	
236	The treatment gap after major osteoporotic fractures in Denmark 2005-2014: a combined analysis including both prescription-based and hospital-administered anti-osteoporosis medications. <i>Osteoporosis International</i> , 2021 , 32, 1961-1971	5.3	1
235	Epidemiology of Tumor-Induced Osteomalacia in Denmark. <i>Calcified Tissue International</i> , 2021 , 109, 147-156	3.56	6
234	A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease. <i>Endocrine</i> , 2021 , 73, 509-529	4	4
233	Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies. <i>JBMR Plus</i> , 2021 , 5, e10522	3.9	2
232	Validation of the Fracture Risk Evaluation Model (FREM) in predicting major osteoporotic fractures and hip fractures using administrative health data. <i>Bone</i> , 2021 , 147, 115934	4.7	5
231	Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 24-40	6.3	6
230	Response to Shao Et Al. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 619-620	6.3	
229	Does treatment with bisphosphonates protect against fractures in real life? The HUNT study, Norway. <i>Osteoporosis International</i> , 2021 , 32, 1395-1404	5.3	0

228	A comparison of fracture risk assessment tools 2021 , 1589-1609		0
227	Bisphosphonate Drug Holidays in Primary Care: When and What to Do Next?. <i>Current Osteoporosis Reports</i> , 2021 , 19, 182-188	5.4	4
226	Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 820-832	6.3	9
225	Accelerated osteoarthritis in women with polycystic ovary syndrome: a prospective nationwide registry-based cohort study. <i>Arthritis Research and Therapy</i> , 2021 , 23, 225	5.7	1
224	One- and 2-year incidence of osteoporotic fracture: a multi-cohort observational study using routinely collected real-world data. <i>Osteoporosis International</i> , 2021 , 1	5.3	1
223	Predicting Imminent Fractures in Patients With a Recent Fracture or Starting Oral Bisphosphonate Therapy: Development and International Validation of Prognostic Models. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 2162-2176	6.3	2
222	Prediction of imminent fracture risk in Canadian women and men aged 45 years or older: external validation of the Fracture Risk Evaluation Model (FREM). <i>Osteoporosis International</i> , 2021 , 1	5.3	4
221	Diabetes increases the risk of bone fractures in patients on kidney replacement therapy: A Danish national cohort study. <i>Bone</i> , 2021 , 153, 116158	4.7	
220	Secular trends in the initiation of therapy in secondary fracture prevention in Europe: a multi-national cohort study including data from Denmark, Catalonia, and the United Kingdom. <i>Osteoporosis International</i> , 2020 , 31, 1535-1544	5.3	16
219	Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries. <i>Bone</i> , 2020 , 134, 115296	4.7	3
218	Assessment of fracture risk in women with eating disorders: The utility of dual-energy x-ray absorptiometry (DXA)-Clinical cohort study. <i>International Journal of Eating Disorders</i> , 2020 , 53, 595-605	6.3	2
217	Oral Bisphosphonate Use and All-Cause Mortality in Patients With Moderate-Severe (Grade 3B-5D) Chronic Kidney Disease: A Population-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 894-900	6.3	6
216	Fractures in women with eating disorders-Incidence, predictive factors, and the impact of disease remission: Cohort study with background population controls. <i>International Journal of Eating Disorders</i> , 2020 , 53, 1080-1087	6.3	8
215	The association between renal function and BMD response to bisphosphonate treatment: Real-world cohort study using linked national registers. <i>Bone</i> , 2020 , 137, 115371	4.7	3
214	OR13-03 Understanding Why Older People with Low Trauma Fractures Die Prematurely. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	78
213	Proton pump inhibitors and fracture risk. The HUNT study, Norway. <i>Osteoporosis International</i> , 2020 , 31, 109-118	5.3	12
212	Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	18
211	Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	5

210	Nutrients, Diet, and Other Factors in Prenatal Life and Bone Health in Young Adults: A Systematic Review of Longitudinal Studies. <i>Nutrients</i> , 2020 , 12,	6.7	7
209	Pre-fracture medication use as a predictor of 30-day mortality in hip fracture patients: an analysis of 141,201 patients. <i>HIP International</i> , 2020 , 30, 101-106	1.7	4
208	The Latest Evidence from Vitamin D Intervention Trials for Skeletal and Non-skeletal Outcomes. <i>Calcified Tissue International</i> , 2020 , 106, 88-93	3.9	2
207	Age at hip fracture and life expectancy in Denmark - Secular trends over two decades. <i>Bone</i> , 2020 , 130, 115083	4.7	9
206	Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 ,	5.6	43
205	Biochemical markers of inflammation are associated with increased mortality in hip fracture patients: the Bispebjerg Hip Fracture Biobank. <i>Aging Clinical and Experimental Research</i> , 2019 , 31, 1727-1734	4.8	12
204	Fracture risk following intermission of osteoporosis therapy. <i>Osteoporosis International</i> , 2019 , 30, 1733-1743	5.4	25
203	Excess mortality following hip fracture in patients with diabetes according to age: a nationwide population-based cohort study of 154,047 hip fracture patients. <i>Age and Ageing</i> , 2019 , 48, 559-563	3	4
202	Osteoporosis; Prevention and Ca ²⁺ Vitamin D Treatment 2019 , 270-274		
201	Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). <i>Osteoporosis International</i> , 2019 , 30, 2155-2165	5.3	30
200	Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2150-2158	15.1	29
199	Increased risk of thyroid disease in Danish women with polycystic ovary syndrome: a cohort study. <i>Endocrine Connections</i> , 2019 , 8, 1405-1415	3.5	7
198	Duration of over- and under-treatment of hypothyroidism is associated with increased cardiovascular risk. <i>European Journal of Endocrinology</i> , 2019 , 180, 407-416	6.5	25
197	Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. <i>Endocrine Reviews</i> , 2019 , 40, 333-368	27.2	92
196	Osteoporosis and prostate cancer; a 24-month prospective observational study during androgen deprivation therapy. <i>Scandinavian Journal of Urology</i> , 2019 , 53, 34-39	1.6	16
195	Long term time trends in use of medications associated with risk of developing osteoporosis: Nationwide data for Denmark from 1999 to 2016. <i>Bone</i> , 2019 , 120, 94-100	4.7	11
194	Side effects of drugs for osteoporosis and metastatic bone disease. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1063-1071	3.8	38
193	Hip fracture rates and time trends in use of anti-osteoporosis medications in Denmark for the period 2005 to 2015: Missed opportunities in fracture prevention. <i>Bone</i> , 2019 , 120, 476-481	4.7	17

192	Duration of Hyperthyroidism and Lack of Sufficient Treatment Are Associated with Increased Cardiovascular Risk. <i>Thyroid</i> , 2019 , 29, 332-340	6.2	47
191	Socioeconomic status in Danish women with polycystic ovary syndrome: A register-based cohort study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2019 , 98, 440-450	3.8	5
190	Over- and Under-Treatment of Hypothyroidism Is Associated with Excess Mortality: A Register-Based Cohort Study. <i>Thyroid</i> , 2018 , 28, 566-574	6.2	54
189	Response to Letter to the Editor: "Development and Risk Factors of Type 2 Diabetes in a Nationwide Population of Women With Polycystic Ovary Syndrome". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 362-363	5.6	3
188	Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. <i>Cardiovascular Diabetology</i> , 2018 , 17, 37	8.7	89
187	The Changing Role of Patient Education in Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 761-762	6.3	2
186	Danish, national cross-sectional observational study on the prevalence of prior major osteoporotic fractures in adults presenting with hip fracture-limitations and scope for fracture liaison services in prevention of hip fracture. <i>Osteoporosis International</i> , 2018 , 29, 109-114	5.3	8
185	A New Fracture Risk Assessment Tool (FREM) Based on Public Health Registries. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1967-1979	6.3	15
184	Diagnosis and management of bone fragility in diabetes: an emerging challenge. <i>Osteoporosis International</i> , 2018 , 29, 2585-2596	5.3	141
183	Persistence of Excess Mortality Following Individual Nonhip Fractures: A Relative Survival Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 3205-3214	5.6	32
182	Risk factors for post peak bone loss and osteoporotic fracture: Lessons from population studies 2018 , 123-152		
181	Clinical improvement in a patient with monostotic melorheostosis after treatment with denosumab: a case report. <i>Journal of Medical Case Reports</i> , 2018 , 12, 278	1.2	7
180	High calcium intake in men not women is associated with all-cause mortality risk: Melbourne Collaborative Cohort Study. <i>Archives of Osteoporosis</i> , 2018 , 13, 101	2.9	5
179	Adverse Effects of Drugs for Osteoporosis 2018 , 579-587		
178	Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway. <i>Osteoporosis International</i> , 2018 , 29, 1875-1885	5.3	9
177	Social inequality and fractures-secular trends in the Danish population: a case-control study. <i>Osteoporosis International</i> , 2018 , 29, 2243-2250	5.3	12
176	International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. <i>Osteoporosis International</i> , 2017 , 28, 767-774	5.3	77
175	Hyperkalemia is Associated with Increased 30-Day Mortality in Hip Fracture Patients. <i>Calcified Tissue International</i> , 2017 , 101, 9-16	3.9	14

174	Recent hip fracture trends in Sweden and Denmark with age-period-cohort effects. <i>Osteoporosis International</i> , 2017 , 28, 139-149	5.3	46
173	Prenatal exposure to vitamin D from fortified margarine and risk of fractures in late childhood: period and cohort results from 222 000 subjects in the D-TECT observational study. <i>British Journal of Nutrition</i> , 2017 , 117, 872-881	3.6	2
172	The calcium and vitamin D controversy. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017 , 9, 107-114	8.8	19
171	Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. <i>Osteoporosis International</i> , 2017 , 28, 2023-2034	5.3	88
170	Reply to: systematic review and meta-analysis for the association of bone mineral density and osteoporosis/osteopenia with vascular calcification in women. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 2144-2145	2.3	
169	Neonatal vitamin D status from archived dried blood spots and future risk of fractures in childhood: results from the D-TECT study, a population-based case-cohort study. <i>American Journal of Clinical Nutrition</i> , 2017 , 106, 155-161	7	18
168	Excess Mortality in Treated and Untreated Hyperthyroidism Is Related to Cumulative Periods of Low Serum TSH. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2301-2309	5.6	52
167	Development and Risk Factors of Type 2 Diabetes in a Nationwide Population of Women With Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 3848-3857	5.6	90
166	Excess of all-cause mortality after a fracture in type 2 diabetic patients: a population-based cohort study. <i>Osteoporosis International</i> , 2017 , 28, 2573-2581	5.3	13
165	Evidence for the prevention of bone loss in elderly and old early non-metastatic breast cancer patients treated with aromatase inhibitors. <i>European Geriatric Medicine</i> , 2017 , 8, 408-412	3	1
164	Women@ lived experiences of learning to live with osteoporosis: a longitudinal qualitative study. <i>BMC Women's Health</i> , 2017 , 17, 17	2.9	12
163	Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users. <i>Osteoporosis International</i> , 2017 , 28, 2921-2928	5.3	21
162	Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway. <i>Osteoporosis International</i> , 2017 , 28, 2935-2944	5.3	20
161	Epidemiology of Fractures in Diabetes. <i>Calcified Tissue International</i> , 2017 , 100, 109-121	3.9	43
160	Mechanisms of diabetes mellitus-induced bone fragility. <i>Nature Reviews Endocrinology</i> , 2017 , 13, 208-219	5.2	41
159	Fracture Rates and Fracture Sites in Patients With Osteogenesis Imperfecta: A Nationwide Register-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 125-134	6.3	60
158	The risk of osteoporosis in oral steroid treatment for nasal polyposis: a systematic review. <i>Rhinology</i> , 2017 , 55, 195-201	7	2
157	The risk of osteoporosis in oral steroid treatment for nasal polyposis: a systematic review. <i>Rhinology</i> , 2017 , 55, 195-201	7	10

156	Diagnostic devices for osteoporosis in the general population: A systematic review. <i>Bone</i> , 2016 , 92, 58-62.	4.7	29
155	Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. <i>BMJ, The</i> , 2016 , 353, i3365	5.9	55
154	Proton pump inhibitors and osteoporosis. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 420-5	5.3	50
153	Risk of fracture in adults on renal replacement therapy: a Danish national cohort study. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1654-62	4.3	42
152	Low Levels of Hemoglobin at Admission Are Associated With Increased 30-Day Mortality in Patients With Hip Fracture. <i>Geriatric Orthopaedic Surgery and Rehabilitation</i> , 2016 , 7, 115-20	2	10
151	Temporal trends in the use of antithrombotics at admission. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2016 , 87, 368-73	4.3	11
150	Hyponatremia and hypernatremia are associated with increased 30-day mortality in hip fracture patients. <i>Osteoporosis International</i> , 2016 , 27, 397-404	5.3	24
149	Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 234-44	6.3	14
148	Fracture Risk Is Decreased in Women With Polycystic Ovary Syndrome: A Register-Based and Population-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 709-17	6.3	20
147	Patients With Atypical Femur Fractures Have the Same Mortality as the Background Population--Drug-Channeling Bias, Bisphosphonate Effects, and Public Health Implications. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 488-90	6.3	5
146	Risks and Benefits of Bisphosphonate Therapies. <i>Journal of Cellular Biochemistry</i> , 2016 , 117, 20-8	4.7	76
145	The epidemiology of fractures in Denmark in 2011. <i>Osteoporosis International</i> , 2016 , 27, 2017-25	5.3	28
144	Real-Life and RCT Participants: Alendronate Users Versus FITS Trial Eligibility Criterion. <i>Calcified Tissue International</i> , 2016 , 99, 243-9	3.9	22
143	Cardiovascular disease in patients with osteogenesis imperfecta - a nationwide, register-based cohort study. <i>International Journal of Cardiology</i> , 2016 , 225, 250-257	3.2	15
142	Maternal serum retinol and β -carotene concentrations and neonatal bone mineralization: results from the Southampton Women's Survey cohort. <i>American Journal of Clinical Nutrition</i> , 2016 , 104, 1183-1188	7.88	16
141	Mortality and Causes of Death in Patients With Osteogenesis Imperfecta: A Register-Based Nationwide Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 2159-2166	6.3	55
140	Life Expectancy in Patients Treated for Osteoporosis: Observational Cohort Study Using National Danish Prescription Data. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 1553-9	6.3	14
139	Vitamin D insufficiency is associated with increased risk of first-trimester miscarriage in the Odense Child Cohort. <i>American Journal of Clinical Nutrition</i> , 2015 , 102, 633-8	7	52

138	Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2015 , 172, 627-38	6.5	83
137	Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective. <i>Osteoporosis International</i> , 2015 , 26, 513-9	5.3	39
136	A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 1335-42	5.6	80
135	Is allopurinol use associated with an excess risk of osteoporotic fracture? A National Prescription Registry study. <i>Archives of Osteoporosis</i> , 2015 , 10, 36	2.9	16
134	Nutrient and food intakes in early life and risk of childhood fractures: a systematic review and meta-analysis. <i>American Journal of Clinical Nutrition</i> , 2015 , 102, 1182-95	7	34
133	Bone: Sequential osteoporosis treatment--the order of things. <i>Nature Reviews Endocrinology</i> , 2015 , 11, 570-2	15.2	1
132	The excess risk of major osteoporotic fractures in hypothyroidism is driven by cumulative hyperthyroid as opposed to hypothyroid time: an observational register-based time-resolved cohort analysis. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 898-905	6.3	48
131	Epidemiology of forearm fractures in adults in Denmark: national age- and gender-specific incidence rates, ratio of forearm to hip fractures, and extent of surgical fracture repair in inpatients and outpatients. <i>Osteoporosis International</i> , 2015 , 26, 67-76	5.3	24
130	Use of anti-osteoporotic drugs in central Norway after a forearm fracture. <i>Archives of Osteoporosis</i> , 2015 , 10, 235	2.9	10
129	Denosumab: a novel antiresorptive drug for osteoporosis. <i>Cleveland Clinic Journal of Medicine</i> , 2015 , 82, 105-14	2.8	10
128	Safety issues with bisphosphonate therapy for osteoporosis. <i>Rheumatology</i> , 2014 , 53, 19-31	3.9	102
127	Status of drug development for the prevention and treatment of osteoporosis. <i>Expert Opinion on Drug Discovery</i> , 2014 , 9, 245-53	6.2	16
126	Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. <i>Osteoporosis International</i> , 2014 , 25, 757-62	5.3	49
125	Comment on Tadrous et al.: comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. <i>Osteoporosis International</i> , 2014 , 25, 2669	5.3	1
124	A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures. <i>BoneKey Reports</i> , 2014 , 3, 574		26
123	Duration of thyroid dysfunction correlates with all-cause mortality. the OPENTHYRO Register Cohort. <i>PLoS ONE</i> , 2014 , 9, e110437	3.7	50
122	Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures-the OPENTHYRO register cohort. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 2040-50	6.3	73
121	Women@ experiences of their osteoporosis diagnosis at the time of diagnosis and 6 months later: a phenomenological hermeneutic study. <i>International Journal of Qualitative Studies on Health and Well-being</i> , 2014 , 9, 22438	2	23

120	Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1123-9	2.4	23
119	Response: Is heart failure a debatable end-point for bisphosphonate treatment in an older osteoporotic population?. <i>Journal of Internal Medicine</i> , 2014 , 275, 198	10.8	
118	Oral bisphosphonate use and total knee/hip implant survival: validation of results in an external population-based cohort. <i>Arthritis and Rheumatology</i> , 2014 , 66, 3233-40	9.5	27
117	Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy. <i>Scandinavian Journal of Urology</i> , 2014 , 48, 350-5	1.6	6
116	Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 1-23	6.3	935
115	Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases. <i>Osteoporosis International</i> , 2013 , 24, 2639-47	5.7	25
114	Anti-osteoporotic therapy in Denmark--predictors and demographics of poor refill compliance and poor persistence. <i>Osteoporosis International</i> , 2013 , 24, 2079-97	5.3	28
113	Time trends for alendronate prescription practices in women with chronic obstructive pulmonary disease and women exposed to systemic glucocorticoids. <i>Osteoporosis International</i> , 2013 , 24, 1891-7	5.3	4
112	Bisphosphonates and colon cancer: reply. <i>Osteoporosis International</i> , 2013 , 24, 1141-2	5.3	
111	The influence of early exposure to vitamin D for development of diseases later in life. <i>BMC Public Health</i> , 2013 , 13, 515	4.1	19
110	The bisphosphonates: risks and benefits of long term use. <i>Current Opinion in Pharmacology</i> , 2013 , 13, 435-9	5.1	17
109	Parity and tanned white skin as novel predictors of vitamin D status in early pregnancy: a population-based cohort study. <i>Clinical Endocrinology</i> , 2013 , 79, 333-41	3.4	60
108	Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 455-63	6.3	24
107	Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database. <i>Osteoporosis International</i> , 2013 , 24, 369-72	5.3	10
106	Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study. <i>Osteoporosis International</i> , 2013 , 24, 245-52	5.3	53
105	Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study. <i>Osteoporosis International</i> , 2013 , 24, 321-8	5.3	18
104	Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data. <i>Bone</i> , 2013 , 57, 269-71	4.7	32
103	Comparison of different screening tools (FRAX [®] , OST, ORAI, OSIRIS, SCORE and age alone) to identify women with increased risk of fracture. A population-based prospective study. <i>Bone</i> , 2013 , 56, 16-22	4.7	67

102	Risk assessment tools to identify women with increased risk of osteoporotic fracture: complexity or simplicity? A systematic review. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 1701-17	6.3	119
101	The role of vitamin D supplementation in patients with rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2013 , 9, 411-22	8.1	10
100	Central nervous system medications and falls risk in men aged 60-75 years: the Study on Male Osteoporosis and Aging (SOMA). <i>Age and Ageing</i> , 2013 , 42, 121-4	3	21
99	Heart failure in patients treated with bisphosphonates. <i>Journal of Internal Medicine</i> , 2013 , 274, 342-50	10.8	18
98	Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted. <i>BMJ, The</i> , 2013 , 346, f1514	5.9	
97	Eliminating the need for fasting with oral administration of bisphosphonates. <i>Therapeutics and Clinical Risk Management</i> , 2013 , 9, 395-402	2.9	33
96	Risk factors for fracture in elderly men: a population-based prospective study. <i>Osteoporosis International</i> , 2012 , 23, 521-31	5.3	18
95	Pattern of use of DXA scans in men: a cross-sectional, population-based study. <i>Osteoporosis International</i> , 2012 , 23, 183-91	5.3	12
94	Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study. <i>Osteoporosis International</i> , 2012 , 23, 2693-701	5.3	61
93	Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. <i>Osteoporosis International</i> , 2012 , 23, 2873-84	5.3	22
92	Essentials in rheumatology: disease management134. Metabolic bone diseases. <i>Rheumatology</i> , 2012 , 51, iii7-iii13	3.9	
91	Beyond a reasonable doubt? Bisphosphonates and atypical femur fractures. <i>Bone</i> , 2012 , 50, 1196-200	4.7	19
90	Antidepressant medications and osteoporosis. <i>Bone</i> , 2012 , 51, 606-13	4.7	118
89	A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 3161-9	5.6	138
88	Season of birth and the risk of hip fracture in danish men and women aged 65+. <i>Frontiers in Endocrinology</i> , 2012 , 3, 2	5.7	12
87	Esophageal and gastric cancer incidence and mortality in alendronate users. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 679-86	6.3	46
86	Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 1405-12	6.3	44
85	Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 2670-81	5.6	160

84	Disentangling the emerging evidence around atypical fractures. <i>Current Rheumatology Reports</i> , 2012 , 14, 212-6	4.9	5
83	Osteoporosis and vertebral fractures in men aged 60-74 years. <i>Age and Ageing</i> , 2012 , 41, 171-7	3	37
82	Safety of bisphosphonates. <i>Bone</i> , 2011 , 49, 103-10	4.7	102
81	Effects of COL1A1 polymorphisms and haplotypes on perimenopausal bone mass, postmenopausal bone loss and fracture risk. <i>Osteoporosis International</i> , 2011 , 22, 1145-56	5.3	13
80	Prevalence of risk factors for fractures and use of DXA scanning in Danish women. A regional population-based study. <i>Osteoporosis International</i> , 2011 , 22, 1401-9	5.3	32
79	Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results. <i>Osteoporosis International</i> , 2011 , 22, 1493-501	5.3	21
78	Do calcium plus vitamin D supplements increase cardiovascular risk?. <i>BMJ, The</i> , 2011 , 342, d2080	5.9	30
77	Older women who use bisphosphonate for longer than 5 years may have increased odds of a subtrochanteric or femoral shaft fracture, but absolute risk is low. <i>Evidence-Based Medicine</i> , 2011 , 16, 168-9		7
76	Fracture risk assessed by Fracture Risk Assessment Tool (FRAX) compared with fracture risk derived from population fracture rates. <i>Scandinavian Journal of Public Health</i> , 2011 , 39, 312-8	3	14
75	Inverse Association Between Duration of Use of Acid-Suppressive Medications and Fracture RiskReply. <i>Archives of Internal Medicine</i> , 2011 , 171, 1044		
74	Proton pump inhibitor use and the antifracture efficacy of alendronate. <i>Archives of Internal Medicine</i> , 2011 , 171, 998-1004		60
73	Vitamin D status and PTH in young men: a cross-sectional study on associations with bone mineral density, body composition and glucose metabolism. <i>Clinical Endocrinology</i> , 2010 , 73, 573-80	3.4	45
72	Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. <i>Age and Ageing</i> , 2010 , 39, 203-9	3	343
71	Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. <i>BMJ, The</i> , 2010 , 340, b5463	5.9	264
70	Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 5258-65	5.6	128
69	Bisphosphonate adverse effects, lessons from large databases. <i>Current Opinion in Rheumatology</i> , 2010 , 22, 404-9	5.3	48
68	Adverse effects of bisphosphonates. <i>Calcified Tissue International</i> , 2010 , 86, 421-35	3.9	108
67	Adiponectin and peak bone mass in men: a cross-sectional, population-based study. <i>Calcified Tissue International</i> , 2010 , 87, 36-43	3.9	10

66	Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997-2006. <i>Osteoporosis International</i> , 2010 , 21, 373-80	5.3	119
65	Validation of a 5-year risk score of hip fracture in postmenopausal women. The Danish Nurse Cohort Study. <i>Osteoporosis International</i> , 2010 , 21, 2135-42	5.3	8
64	Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 2267-94	6.3	840
63	More on reports of esophageal cancer with oral bisphosphonate use. <i>New England Journal of Medicine</i> , 2009 , 360, 1789; author reply 1791-2	59.2	66
62	No association between hip geometry and four common polymorphisms associated with fracture: the Danish osteoporosis prevention study. <i>Calcified Tissue International</i> , 2009 , 84, 276-85	3.9	14
61	Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. <i>Osteoporosis International</i> , 2009 , 20, 299-307	5.3	60
60	Mapping the prescripiome to fractures in men--a national analysis of prescription history and fracture risk. <i>Osteoporosis International</i> , 2009 , 20, 585-97	5.3	30
59	Excess mortality following hip fracture: a systematic epidemiological review. <i>Osteoporosis International</i> , 2009 , 20, 1633-50	5.3	650
58	Atrial fibrillation in fracture patients treated with oral bisphosphonates. <i>Journal of Internal Medicine</i> , 2009 , 265, 581-92	10.8	90
57	Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 1095-102	6.3	275
56	Prevention and treatment of osteoporosis in women: an update. <i>Obstetrics, Gynaecology and Reproductive Medicine</i> , 2009 , 19, 157-163	0.5	2
55	Changes in bone mineral density (BMD) around the cemented Exeter stem: a prospective study in 18 women with 5 years follow-up. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2008 , 79, 494-8	4.3	17
54	Abnormal muscle and hematopoietic gene expression may be important for clinical morbidity in primary hyperparathyroidism. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007 , 292, E1465-73	6	29
53	Fracture risk in Danish men with prostate cancer: a nationwide register study. <i>BJU International</i> , 2007 , 100, 749-54	5.6	64
52	Disproportional geometry of the proximal femur in patients with Turner syndrome: a cross-sectional study. <i>Clinical Endocrinology</i> , 2007 , 67, 897-903	3.4	13
51	Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with peak bone mass in non-sedentary men: results from the Odense androgen study. <i>Calcified Tissue International</i> , 2007 , 81, 421-9	3.9	29
50	Comment on Schott et al.: which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. <i>Osteoporosis International</i> , 2007 , 18, 699; author reply 701	5.3	
49	Estimates of fracture probability in Denmark: reply to Johansson et al. <i>Osteoporosis International</i> , 2007 , 18, 1145-1146	5.3	1

48	Population-based reference values for bone mineral density in young men. <i>Osteoporosis International</i> , 2007 , 18, 1507-14	5.3	41
47	Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 555-67	1.9	82
46	Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. <i>Thrombosis and Haemostasis</i> , 2007 , 97, 234-239	7	7
45	MTHFR c.677C>T polymorphism as an independent predictor of peak bone mass in Danish men--results from the Odense Androgen Study. <i>Bone</i> , 2006 , 38, 215-9	4.7	35
44	Gene expression profiles give insight into the molecular pathology of bone in primary hyperparathyroidism. <i>Bone</i> , 2006 , 39, 189-98	4.7	25
43	Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: Results from the Danish Osteoporosis Prevention Study (DOPS). <i>Thrombosis and Haemostasis</i> , 2006 , 95, 915-916	7	4
42	Ten-year absolute risk of osteoporotic fractures according to BMD T score at menopause: the Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2006 , 21, 796-800	6.3	37
41	Ten-year prediction of osteoporosis from baseline bone mineral density: development of prognostic thresholds in healthy postmenopausal women. The Danish Osteoporosis Prevention Study. <i>Osteoporosis International</i> , 2006 , 17, 245-51	5.3	12
40	Ten year absolute risk of osteoporotic fractures according to BMD T-score at menopause. The Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2006 , 061114081131043-18	6.3	37
39	Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study. <i>BMJ, The</i> , 2005 , 330, 818	5.9	38
38	Prevention and treatment of osteoporosis in women. <i>Current Obstetrics & Gynaecology</i> , 2005 , 15, 251-258		4
37	Are effects of MTHFR (C677T) genotype on BMD confined to women with low folate and riboflavin intake? Analysis of food records from the Danish osteoporosis prevention study. <i>Bone</i> , 2005 , 36, 577-83	4.7	51
36	Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. <i>Bone</i> , 2005 , 36, 727-35	4.7	41
35	Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures. <i>Calcified Tissue International</i> , 2005 , 76, 90-7	3.9	57
34	Performance of four clinical screening tools to select peri- and early postmenopausal women for dual X-ray absorptiometry. <i>Osteoporosis International</i> , 2005 , 16, 764-72	5.3	27
33	Geometry of the proximal femur in relation to age and sex: a cross-sectional study in healthy adult Danes. <i>Acta Radiologica</i> , 2005 , 46, 514-8	2	24
32	Technology evaluation: denosumab, Amgen. <i>Current Opinion in Molecular Therapeutics</i> , 2005 , 7, 604-10		9
31	Dose-, IGF-I- and sex-dependent changes in lipid profile and body composition during GH replacement therapy in adult onset GH deficiency. <i>European Journal of Endocrinology</i> , 2004 , 150, 671-9	6.5	14

30	Two single nucleotide polymorphisms in the CYP17 and COMT Genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy. The Danish Osteoporosis Prevention Study. <i>Calcified Tissue International</i> , 2004 , 75, 123-32	3.9	22
29	Polymorphisms in the CYP19 and AR genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study. <i>Calcified Tissue International</i> , 2004 , 74, 25-34	3.9	43
28	Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappa ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. <i>Bone</i> , 2004 , 35, 256-65	4.7	44
27	Response rates to oestrogen treatment in perimenopausal women: 5-year data from the Danish Osteoporosis Prevention Study (DOPS). <i>Maturitas</i> , 2004 , 48, 307-20	5	6
26	Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 333-42	6.3	84
25	A common methylenetetrahydrofolate reductase (C677T) polymorphism is associated with low bone mineral density and increased fracture incidence after menopause: longitudinal data from the Danish osteoporosis prevention study. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 723-9	6.3	81
24	Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6. <i>Calcified Tissue International</i> , 2003 , 72, 18-23	3.9	16
23	Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. <i>Calcified Tissue International</i> , 2003 , 73, 210-6	3.9	28
22	Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 1208-14	15.4	30
21	Standardization of BMD T-Scores in the first five years after the menopause: do femoral neck-equivalent and older normative range T-Scores improve diagnostic agreement?. <i>Journal of Clinical Densitometry</i> , 2003 , 6, 87-95	3.5	3
20	Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: a randomized controlled study. <i>American Journal of Obstetrics and Gynecology</i> , 2002 , 187, 33-9	6.4	51
19	Association of a common allelic polymorphism (C677T) in the methylene tetrahydrofolate reductase gene with a reduced risk of osteoporotic fractures. A case control study in Danish postmenopausal women. <i>Calcified Tissue International</i> , 2002 , 71, 386-92	3.9	60
18	Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies. <i>Clinical Endocrinology</i> , 2002 , 57, 273-81	3.4	20
17	When should densitometry be repeated in healthy peri- and postmenopausal women: the Danish osteoporosis prevention study. <i>Journal of Bone and Mineral Research</i> , 2002 , 17, 2061-7	6.3	13
16	Two polymorphisms in the vitamin D receptor gene--association with bone mass and 5-year change in bone mass with or without hormone-replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2002 , 17, 1535-44	6.3	25
15	Discordance between changes in bone mineral density measured at different skeletal sites in perimenopausal women--implications for assessment of bone loss and response to therapy: The Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2001 , 16, 1212-9	6.3	35
14	Evaluation of methods for prediction of bone mineral density by clinical and biochemical variables in perimenopausal women. <i>Maturitas</i> , 2001 , 40, 211-20	5	30
13	Correlations between insulin sensitivity and bone mineral density in non-diabetic men. <i>Diabetic Medicine</i> , 2000 , 17, 124-9	3.5	89

12	Cytokines and bone loss in a 5-year longitudinal study--hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2000 , 15, 1545-54	6.3	68
11	Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. <i>Maturitas</i> , 2000 , 36, 181-93	5	118
10	Cytokine RNA levels in transiliac bone biopsies from healthy early postmenopausal women. <i>Bone</i> , 2000 , 26, 137-45	4.7	30
9	Vitamin D receptor alleles do not predict bone mineral density or bone loss in Danish perimenopausal women. <i>Bone</i> , 1998 , 22, 571-5	4.7	40
8	Diagnosis of osteoporosis by planar bone densitometry: can body size be disregarded?. <i>British Journal of Radiology</i> , 1998 , 71, 934-43	3.4	32
7	Cytokines and T-lymphocyte subsets in healthy post-menopausal women: estrogen retards bone loss without affecting the release of IL-1 or IL-1ra. <i>Bone</i> , 1997 , 20, 251-8	4.7	38
6	Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. <i>Maturitas</i> , 1997 , 28, 137-45	5	53
5	Site of osteodensitometry in perimenopausal women: correlation and limits of agreement between anatomic regions. <i>Journal of Bone and Mineral Research</i> , 1997 , 12, 1471-9	6.3	57
4	Impact of hemodialysis on dual X-ray absorptiometry, bioelectrical impedance measurements, and anthropometry. <i>American Journal of Clinical Nutrition</i> , 1996 , 63, 80-6	7	80
3	Cross calibration of QDR-2000 and QDR-1000 dual-energy X-ray densitometers for bone mineral and soft-tissue measurements. <i>Bone</i> , 1995 , 16, 385-90	4.7	144
2	Relevance of Ki-67 expression in the classification of non-Hodgkin $\text{\textcircled{R}}$ lymphomas: a morphometric and double-immunostaining study. <i>Histopathology</i> , 1992 , 20, 13-20	7.3	11
1	Age at first major osteoporotic fracture in Danes aged 50 and over: influence of diabetes on mean age at fracture and 1 year mortality. <i>Endocrine Abstracts</i> ,		2